PDB70 - ECONOMIC EVALUATION OF THE USE OF RECOMBINANT HUMAN EPIDERMAL GROWTH FACTOR (HEBERPROT-P®) AS AN ADJUVANT OF CONVENTIONAL THERAPY FOR THE TREATMENT OF DIABETIC FOOT ULCER
Abstract
Authors
V. Muzio O. Gonzalez D. Garcia B. Flores J.L. Alcantara A. Figueroa F. Lemus